INSM

Insmed Incorporated [INSM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

INSM Stock Summary

Earnings have grown 24.39% per last year.

The Moving Average Convergence Divergence (MACD) for INSM recently turned positive (within last 10 days).

Top 10 Correlated ETFs

INSM

Top 10 Correlated Stocks

INSM

In the News

INSM Financial details

Company Rating

Market Cap

4.05B

Income

-749.57M

Revenue

305.21M

Book val./share

Cash/share

Dividend

Dividend %

Employees

912

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-5.34

Forward P/E

PEG

-1.46

P/S

13.46

P/B

-12.07

P/C

P/FCF

-7.47

Quick Ratio

3.64

Current Ratio

4.12

Debt / Equity

LT Debt / Equity

EPS (TTM)

-5.34

EPS next Y

EPS next Q

EPS this Y

36.57%

EPS next Y

EPS next 5Y

EPS last 5Y

12.15%

Revenue last 5Y

17.47%

Revenue Q/Q

5.84%

EPS Q/Q

15.32%

SMA20

-4.9%

SMA50

12.22%

SMA100

4.7%

Inst Own

Inst Trans

ROA

-56%

ROE

365%

ROC

-0.65%

Gross Margin

79%

Oper. Margin

-236%

Profit Margin

-246%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

16.46-32.0

52W High

+149.75%

52W Low

+399.5%

RSI

57.81

Rel Volume

1.17

Avg Volume

1.63M

Volume

1.91M

Perf Week

7.94%

Perf Month

-1.06%

Perf Quarter

9.67%

Perf Half Y

9.67%

Beta

0.915

Volatility

1.53%, 2.66%

Prev Close

1.46%

Price

79.92

Change

1.67%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.63M
Market Capitalization 4.05B
Employee 912
CEO Mr. William H. Lewis J.D., M.B.A.
Headquarters Bridgewater,NJ,US
IPO Date 2000-06-01
Website https://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.